Publications by authors named "Marcelo Capra"

Claim this Profile
P
Pirtobrutinib Versus Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Jennifer A Woyach, Lugui Qiu, Sebastian Grosicki, Tomasz Wrobel, Marcelo Capra

J Clin Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.
Paul G Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Marcelo Capra

Blood Cancer J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial.
Kwee Yong, Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Marcelo Capra

Lancet Haematol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Bradley Haverkos, Onder Alpdogan, Robert Baiocchi, Jonathan E Brammer, Tatyana A Feldman, Marcelo Capra

Blood Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Meletios Athanasios Dimopoulos, Vania T M Hungria, Atanas Radinoff, Sosana Delimpasi, Gabor Mikala, Marcelo Capra

Lancet Haematol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Equity program: strategies on clinical studies as an aggregating potential.
Edvan de Queiroz Crusoe, Abrahão Elias Hallack Neto, Deise Ferreira Nantes, Eduardo Flavio Oliveira Ribeiro, Fernando Monteiro Correia Pinto, Marcelo Eduardo Zanella Capra

Hematol Transfus Cell Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
Alexander Lesokhin, Richard LeBlanc, Meletios A Dimopoulos, Marcelo Capra, Carmelo Carlo-Stella

Cancer Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra

Blood Cancer J· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: IKEMA Subgroup Analysis by Prior Transplantation.
Thomas G Martin, Marcelo Capra, Mohamad Mohty, Kenshi Suzuki, Hang Quach

Transplant Cell Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis.
Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour

Haematologica· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Philippe Moreau, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra

Lancet· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Matthew J Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li

Lancet Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, Marcelo Capra, Michele Cavo

Blood· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Frits van Rhee, Jean-François Rossi, David Simpson, Alexander Fosså, Angela Dispenzieri, Marcelo Capra

Br J Haematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M Mark, Marcelo Capra

J Hematol Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of low-level laser for treatment of cancer oral mucositis: a systematic review and meta-analysis.
Fernando Anschau, Jacqueline Webster, Marcelo Eduardo Zanella Capra, André Luis Ferreira de Azeredo da Silva, Airton Tetelbom Stein

Lasers Med Sci· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus bortezomib and dexamethasone bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.
Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Hervé Avet-Loiseau, Tomer M Mark, Marcelo Capra

Haematologica· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Valeria Buccheri, Wolney Gois Barreto, Laura Maria Fogliatto, Marcelo Capra, Mariana Marchiani

Ann Hematol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, P Joy Ho, Andrew Belch, Marcelo Capra

Adv Ther· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
Marina Venzon Antunes, Suziane Raymundo, Sandrine Comparsi Wagner, Vanessa Suñé Mattevi, Natalia Vieira, Marcelo Zanella Capra

Bioanalysis· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
Arnaud Capron, Marina Venzon Antunes, Sandrine Comparsi Wagner, Vanessa Suñe Mattevi, Natalia Vieira, Marcelo Capra

Clin Chim Acta· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
Frits van Rhee, Raymond S Wong, Nikhil Munshi, Jean-Francois Rossi, Xiao-Yan Ke, Marcelo Capra

Lancet Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A safety and feasibility study with platelet lysate expanded bone marrow mesenchymal stromal cells for the treatment of acute graft-versus-host disease in Brazil.
Lucia Silla, Vanessa Valim, Bruna Amorin, Ana Paula Alegretti, Fernanda Dos Santos de Oliveira, Marcelo Capra

Leuk Lymphoma· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome.
Dayane B Koshiyama, Marcelo E Z Capra, Giorgio A Paskulin, Rafael F M Rosa, Ceres A V Oliveira

Ann Hematol· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis